In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Cardiology ,Cardiovascular clinical and economical beneficiary outcomes of tele-cardiology, e- audio-visual cardiology and m-cardiology :TEAM study at multi cardiac centre in India.

Session Poster Session 2

Speaker Naresh Sen

Event : ESC Congress 2019

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Remote Patient Monitoring and Telemedicine
  • Session type : Poster Session

Authors : N Sen (Jaipur,IN), SONAL Tanwar (Jaipur,IN), ASHOK Jain (Jaipur,IN), DEVI Shetty (Bangalore,IN), GEORGE Cherian (Bangalore,IN), BALBIR Kalra (gurgaon,IN), ASHWIN Mehta (Mumbai,IN)

N. Sen1 , S. Tanwar1 , A. Jain2 , D. Shetty3 , G. Cherian3 , B. Kalra4 , A. Mehta5 , 1HG SMS Hospital - Jaipur - India , 2Narayana Hrudayalaya, Cardiology - Jaipur - India , 3Narayana Hrudayalaya Institute of Medical Sciences - Bangalore - India , 4Artemis Hospital, Cardiology - gurgaon - India , 5Kokilaben Dhirubhai Ambani Hospital - Mumbai - India ,

European Heart Journal ( 2019 ) 40 ( Supplement ), 771

Background: Telemedicine has beneficiary aspect to manage health and reduce the burden of illness. It represent health promotion with support of many ways like tele (distance mode), e (electronic mode), audio visual mode and m (mobile or smart phones) mode etc.

Objectives: To evaluate the cardiovascular land economical outcomes of tele-cardiology, e-cardiology, audio-visual cardiology and m-cardiology in large population and to review with increase awareness and application of telemedicine.

Methods: We enrolled 12872 patients from different cardiac centres in india and registered in TEAM (Tele-cardiology, E-cardiology, Audio-visual cardiology and M-cardiology) registry from 2008 to 2018. We included tele diagnosis, tele assistance, tele monitoring, tele therapy, electronic remot media, audio visual media and mobile apps for management of different category of cardiovascular disease like coronary heart and structural heart disease, hypertension, heart failure and congenital heart disorders. We compared TEAM registry with usual group (n=13229) at the platform of beneficiary outcomes regarding diagnostic, therapeutic significance, economical burden, mortality and rate of hospitalization.

Results: Our data revealed that 34% more correction of the diagnosis of congenital heart diseases, 29% reduction of unnecessary transport of acute coronary syndrome and non cardiac chest pain from primary to higher cardiac centre. 38% patients of ST elevation of myocardial infarction were benefited by facilliated angioplasty and 50% mortality risk reduction in TEAM registry as compare usual group. In heart failure patients, 12 months clinical outcomes revealed that there was a significant reduction in rehospitalizations in the TEAM group compared with the usual-care group (19.6% versus 33.7%,) and also found 29% stroke reduction in TEAM group. Usual group showed 2.5 fold higher economical burden than TEAM registry.

Conclusion: Total approach of telemedicine in cardiology service may diagnose correctly at root level, prevent clinical instability, reduce rehospitalization and lower the cost of managing heart patients.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are